位置:首页 > 蛋白库 > BRCA1_BOVIN
BRCA1_BOVIN
ID   BRCA1_BOVIN             Reviewed;        1849 AA.
AC   Q864U1;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   25-MAY-2022, entry version 129.
DE   RecName: Full=Breast cancer type 1 susceptibility protein homolog;
DE            EC=2.3.2.27 {ECO:0000250|UniProtKB:P38398};
DE   AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
GN   Name=BRCA1;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Laurasiatheria; Artiodactyla; Ruminantia; Pecora; Bovidae;
OC   Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND INTERACTION WITH RNA POLYMERASE II.
RX   PubMed=12955082; DOI=10.1038/sj.onc.1206515;
RA   Krum S.A., Womack J.E., Lane T.F.;
RT   "Bovine BRCA1 shows classic responses to genotoxic stress but low in vitro
RT   transcriptional activation activity.";
RL   Oncogene 22:6032-6044(2003).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase that specifically mediates the
CC       formation of 'Lys-6'-linked polyubiquitin chains and plays a central
CC       role in DNA repair by facilitating cellular responses to DNA damage. It
CC       is unclear whether it also mediates the formation of other types of
CC       polyubiquitin chains. The BRCA1-BARD1 heterodimer coordinates a diverse
CC       range of cellular pathways such as DNA damage repair, ubiquitination
CC       and transcriptional regulation to maintain genomic stability. Regulates
CC       centrosomal microtubule nucleation. Required for appropriate cell cycle
CC       arrests after ionizing irradiation in both the S-phase and the G2 phase
CC       of the cell cycle. Required for FANCD2 targeting to sites of DNA
CC       damage. Inhibits lipid synthesis by binding to inactive phosphorylated
CC       ACACA and preventing its dephosphorylation. Contributes to homologous
CC       recombination repair (HRR) via its direct interaction with PALB2, fine-
CC       tunes recombinational repair partly through its modulatory role in the
CC       PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks.
CC       Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation
CC       and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-
CC       mediated ubiquitination of RBBP8. Acts as a transcriptional activator.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000250|UniProtKB:P38398};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Heterodimer with BARD1. Part of the BRCA1-associated genome
CC       surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1,
CC       ATM, BLM, PMS2 and the MRE11-RAD50-NBN protein (MRN) complex. This
CC       association could be a dynamic process changing throughout the cell
CC       cycle and within subnuclear domains. Component of the BRCA1-A complex,
CC       at least composed of BRCA1, BARD1, UIMC1/RAP80, ABRAXAS1, BRCC3/BRCC36,
CC       BABAM2 and BABAM1/NBA1. Interacts (via the BRCT domains) with ABRAXAS1
CC       (phosphorylated form); this is important for recruitment to sites of
CC       DNA damage. Can form a heterotetramer with two molecules of ABRAXAS1
CC       (phosphorylated form). Component of the BRCA1-RBBP8 complex. Interacts
CC       (via the BRCT domains) with RBBP8 ('Ser-327' phosphorylated form); the
CC       interaction ubiquitinates RBBP8, regulates CHEK1 activation, and
CC       involves RBBP8 in BRCA1-dependent G2/M checkpoint control on DNA
CC       damage. Associates with RNA polymerase II holoenzyme. Interacts with
CC       SMC1A, NELFB, DCLRE1C, CLSPN. CHEK1, CHEK2, BAP1, BRCC3, UBXN1 and
CC       PCLAF. Interacts (via BRCT domains) with BRIP1 (phosphorylated form).
CC       Interacts with FANCD2 (ubiquitinated form). Interacts with H2AX
CC       (phosphorylated on 'Ser-140'). Interacts (via the BRCT domains) with
CC       ACACA (phosphorylated form); the interaction prevents dephosphorylation
CC       of ACACA. Part of a BRCA complex containing BRCA1, BRCA2 and PALB2.
CC       Interacts directly with PALB2; the interaction is essential for its
CC       function in HRR. Interacts directly with BRCA2; the interaction occurs
CC       only in the presence of PALB2 which serves as the bridging protein.
CC       Interacts (via the BRCT domains) with LMO4; the interaction represses
CC       the transcriptional activity of BRCA1. Interacts (via the BRCT domains)
CC       with CCAR2 (via N-terminus); the interaction represses the
CC       transcriptional activator activity of BRCA1 (By similarity). Interacts
CC       with EXD2 (By similarity). Interacts (via C-terminus) with DHX9; this
CC       interaction is direct and links BRCA1 to the RNA polymerase II
CC       holoenzyme (By similarity). {ECO:0000250|UniProtKB:P38398,
CC       ECO:0000269|PubMed:12955082}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P38398}.
CC       Chromosome {ECO:0000250|UniProtKB:P48754}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P38398}. Note=Localizes at sites of DNA damage
CC       at double-strand breaks (DSBs); recruitment to DNA damage sites is
CC       mediated by the BRCA1-A complex. Translocated to the cytoplasm during
CC       UV-induced apoptosis. {ECO:0000250|UniProtKB:P38398}.
CC   -!- DOMAIN: The RING-type zinc finger domain interacts with BAP1.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- DOMAIN: The BRCT domains recognize and bind phosphorylated pSXXF motif
CC       on proteins. The interaction with the phosphorylated pSXXF motif of
CC       ABRAXAS1, recruits BRCA1 at DNA damage sites.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Phosphorylated in response to IR, UV, and various stimuli that
CC       cause checkpoint activation, probably by ATM or ATR. Phosphorylation at
CC       Ser-982 by CHEK2 regulates mitotic spindle assembly. Phosphorylation by
CC       AURKA regulates centrosomal microtubule nucleation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   -!- PTM: Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination.
CC       'Lys-6'-linked polyubiquitination does not promote degradation.
CC       {ECO:0000250|UniProtKB:P38398}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY077732; AAL76094.1; -; mRNA.
DR   RefSeq; NP_848668.1; NM_178573.1.
DR   AlphaFoldDB; Q864U1; -.
DR   SMR; Q864U1; -.
DR   BioGRID; 160259; 2.
DR   STRING; 9913.ENSBTAP00000011616; -.
DR   PaxDb; Q864U1; -.
DR   PRIDE; Q864U1; -.
DR   GeneID; 353120; -.
DR   KEGG; bta:353120; -.
DR   CTD; 672; -.
DR   eggNOG; KOG4362; Eukaryota.
DR   InParanoid; Q864U1; -.
DR   OrthoDB; 496760at2759; -.
DR   UniPathway; UPA00143; -.
DR   Proteomes; UP000009136; Unplaced.
DR   GO; GO:0031436; C:BRCA1-BARD1 complex; ISS:UniProtKB.
DR   GO; GO:0005694; C:chromosome; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0070063; F:RNA polymerase binding; ISS:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0045717; P:negative regulation of fatty acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; ISS:UniProtKB.
DR   GO; GO:0085020; P:protein K6-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.40.50.10190; -; 2.
DR   InterPro; IPR011364; BRCA1.
DR   InterPro; IPR031099; BRCA1-associated.
DR   InterPro; IPR025994; BRCA1_serine_dom.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR13763; PTHR13763; 1.
DR   Pfam; PF00533; BRCT; 2.
DR   Pfam; PF12820; BRCT_assoc; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   PIRSF; PIRSF001734; BRCA1; 1.
DR   PRINTS; PR00493; BRSTCANCERI.
DR   SMART; SM00292; BRCT; 2.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF52113; SSF52113; 2.
DR   PROSITE; PS50172; BRCT; 2.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Cell cycle; Chromosome; Cytoplasm; DNA damage;
KW   DNA recombination; DNA repair; DNA-binding; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Isopeptide bond; Lipid biosynthesis;
KW   Lipid metabolism; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Tumor suppressor; Ubl conjugation; Ubl conjugation pathway;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..1849
FT                   /note="Breast cancer type 1 susceptibility protein homolog"
FT                   /id="PRO_0000055827"
FT   DOMAIN          1642..1729
FT                   /note="BRCT 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   DOMAIN          1749..1848
FT                   /note="BRCT 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00033"
FT   ZN_FING         24..65
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          530..558
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          620..662
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          882..912
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1036..1070
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1172..1211
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1321..1389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1392..1419
FT                   /note="Interaction with PALB2"
FT                   /evidence="ECO:0000250"
FT   REGION          1412..1433
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1452..1493
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1562..1590
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1621..1640
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        628..642
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        888..907
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1036..1064
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1325..1339
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1340..1355
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1365..1389
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1461..1493
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1621..1638
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         114
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         423
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         691
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         711
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48754"
FT   MOD_RES         720
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48754"
FT   MOD_RES         982
FT                   /note="Phosphoserine; by CHEK2"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1002
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1211
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1212
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1274
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1330
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1336
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1389
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1418
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1452
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   MOD_RES         1518
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        301
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        339
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        457
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        517
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        981
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
FT   CROSSLNK        1073
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P38398"
SQ   SEQUENCE   1849 AA;  206279 MW;  66354C5D0BAFE8A8 CRC64;
     MDLSADHVEE VQNVLNAMQK ILECPICLEL IKEPVSTKCD HIFCKFCMLK LLNQKKGPSQ
     CPLCKNDITK RSLQESTRFS QLVEELLKII HAFELDTGLQ FANSYNFSRK EDNSPEHLKE
     EVSIIQSMGY RNRAKRLWQS EPENPTLQET SLTVELSNLG IVRSLRTKQQ TQSQNKSVYI
     ELGSDSSEDT VNKASYFSVG DHELLEITPQ GAKAKTNLNP AEKAACEFSE KDITNTEHHQ
     LSIKDLITTQ KHATETHPEK YQGISVSDFH VEPCGTDTHA SSLQHENSSL LLTENRLNVE
     KAEFCNKSKQ PVLVKSQQSR WAESKGTCKD RQIPSTEKKI VLNTDPLYRR KELRKQKPAC
     PDSPGDSQDV PWVTLNNSIQ KVNDWFSRSD EILTSDDSCD GGSESNNEVA GAVEIPNKVD
     GYSGSSEKIN LMASDPHGTL IHERVHSKPV ESNIEDKIFG KTYRRKSSLP NFSHIAEDLI
     LGAFTVEPQI TQEQPLTNKL KCKRRGTSGL QPEDFIKKVD LTIVPKTPEK MTEGTDQTEQ
     KCHGMNITSD GHENKTKRDY VQKEQNANPA ESLEKESVFR TEAEPISISI SNMELELNIH
     RSKAPKNRLK RKSSTRKIPE LELVVSRNPS LPNHTELPID SSSSNEEMKK KHSSQMPVRQ
     SQKLQLIGDK ELTAGAKNNK TYEQINKRLA SDAFPELKLT NTPGYFTNCS SKPEEFVHPS
     LQREENLGTI QVSNSTKDPK DLILREGKAL QIERSVESTN ISLVPDTDYS TQDSISLLEA
     KTPEKAKTAP NPCVSLCTAT KNLKELIHRD FKDTKNNTEG FQDLLGHDIN YVIQETSREM
     EDSELDTQYL QNTFKASKRQ TFALFSNPGN PQKECATVFA HSGSLRDQSP RDPLKCRQKE
     DSQGKSESKS QHVQAICTTV HFPVADQQDR TPGDDAKCSA KEVTRVCQSS QLRGHKTELV
     FANKQGVSEK PNLIPSLSPI KSSVKTICKK SPSEKFEEPV TSPEKTLGSE SIIQSAVSTI
     SQNNIQESTF KEVSSNSVNE VGSSTNEVGS SVNEVGSSGE NIQAEPGRNR EPKLRALLGL
     GLTQPEVYKQ SLPVSNCHHP EIKRQGENED MPQAVKADFS PCLISDNLEQ PTGSRHASQV
     CSETPDNLLN DDEIKENSHF AESDIKERSA VFSESVQKGE FRGSPGPFTH THLAQGHQRG
     AGKLESEETV SSEDEELPCF QQLLFGKVTS TLSPSTGCNT VATEGLSKET EGNLESLKSG
     LNDCSGQVTS AKVSQEHHLN EEARCSGSLF SSQCSAMEDL TTNTNTQDPF LMFERPSKQV
     YQSESEEVLS DKELVSDDEE RETGLEEDSC QEEQSVDSDL GEAVSDHVSE TSLSEDGVGL
     SSQSDILTTQ QRDTMQDNLL KLQQEMAELE AVLERHGSQP SHSSASLTAD SRGPEHLLNL
     EQDTSERAIL TSEKSRDYSR SQNPESLSAD KFPVSLDSST NKNKEPGMER SSASKFQLSY
     NRWYMHSSRS LQDRNCPSQK EPINVADMEE QQLAKREAQD LMGSFLPRQD QEGTPYLKSG
     ISLFSHEPES DPSEDRAAEP AHVHSMPPSA SALKLSQFRV EESTKNPAAA HIANTTRCNL
     REESMSKEKP EVISSTERSK KRLSMVASGL TPKELMLVQK FARKHHVTLT NLITEETTHV
     IMKTDPEFVC ERTLKYFLGI AGGKWVVSYF WVTQSIKEGK MLDEHDFEVR GDVVNGRNHQ
     GPKRARESRD KKIFKGLEIC CYGPFTNMPT DQLEWMVQLC GASVVKEPSS FTPDQGTHPV
     VVVQPDAWTE DAGFHVIGQM CEAPVVTREW VLDSVALYQC QELDTYLVP
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024